ReviewBlood advances2026

Targeting BCMA in patients with relapsed/refractory multiple myeloma in 1 to 3 prior lines of therapy.

Doris K Hansen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.